Possibilities for the correction of carbohydrate metabolism disturbances and 24 hours blood pressure profile in patients with chronic heart insufficiency and metabolic syndrome
The data for evaluation of effect of the drug Dibikor (taurine) on carbohydrate metabolism, insulin resistance (IR) and the parameters of the 24 hours blood pressure monitoring in patients with metabolic syndrome (MS) and chronic heart failure (CHF) are presented. The study included 65 men at the age of 31-66 years. Dibikor was added to the main group therapy with enalapril and indapamide. Dibikor administration leads to positive dynamics of anthropometry parameters, carbohydrate metabolism, IR and 24 hours blood pressure monitoring. Thus, the Dibikor use in the treatment of patients with MS and chronic heart failure significantly improves their carbohydrate status, reduces the severity of IR, and promotes more effective control of pre-existing blood pressure disturbances.

Keywords: taurine (Dibikor), daily monitoring of blood pressure, insulin resistance, chronic heart failure, metabolic syndrome